The business strategies of companies involved in chiral drug development were cast into doubt in October after Eli Lilly (Indianapolis, IL) decided not to pursue the development of R-fluoxetine ...

Chiral molecules are like pairs of molecules ... leading to an overall reduction in the potency of the drug,” he says. “As a result, the need for enantiomeric identification and purification ...